September 2018
CanCure presented at Ignite Illinois Technology Showcase on September 27.
August 2018
CanCure Founder, Dr. Wu, Presented at Iummuno-Oncology Summit Annual meeting in Boston.
November 2017
CanCure Founder, Dr. Wu, presented at SITC (Society for Immunotherapy of Cancer) Annual Meeting in MD “Antibody-mediated clearance of soluble MIC significantly enhances response to CTLA4 blockade and reduces therapy-induced colitis “. The presentation was in “SITC 2017 Scientific Highlights - Nov. 10”
October 2017
CanCure LLC was selected by NIH NCI small business initiatives to showcase in Life Science Summit in New York in
October 31-Nov. 01.
August 2017
CanCure Founder and President, Dr. Jennifer Wu, Chaired the Emerging OncoImmune Target session of the IO Summit 2017 in Boston, August 31-Sept 01.
August 2017
CanCure Founder, Dr. Jennifer Wu, accepted a new academic position as an endowed Professor in Feinberg School of Medicine of Northwestern University and Leader of the Cancer Immunology Program at Northwestern Robert Lurie Comprehensive Cancer Center.
June 2017
CanCure technology was featured by BioCentury on June 29, 2017. Article title “DROP THE MIC”.
CanCure LLC was selected by NIH NCI small business initiatives to present in Life Science Summit in New York in October 31-Nov. 01.
May 2017
CanCure participated in the New study published in the high impact scientific Journal Science Advances describing that CuraB10 remarkably enhances responses to immune checkpoint anti-CTLA4 therapy
March 2017
CanCure LLC is accepted into the National Institute of Health’s I-Corps Program, a prestigious entrepreneurial training program designed to accelerate the translation of lab innovations into clinical practice.
January 2017
CanCure received $50,000 as part of the South Carolina Launch SBIR/STTR Phase I Matching Grant Program.
December 18, 2016
CanCure Founder Dr. Jennifer Wu was featured by the Post and Courier
November 30, 2016
CanCure Team was featured in Multourier News, Mount Pleasant, SC
November 2016
CanCure was featured in the SITC (Society for Immunotherapy of Cancer) 31st Annual Meeting Daily Highlights.
November 2017
CanCure Founder, Dr. Wu, presented SITC (Society for Immunotherapy of Cancer) Annual Meeting in MD “Antibody-mediated clearance of soluble MIC significantly enhances response to CTLA4 blockade and reduces therapy-induced colitis “. The presentation was in “SITC 2017 Scientific Highlights - Nov. 10”
October 2016
Dr. Jennifer Wu, CanCure’s Founder and CSO, was featured in the research news article, Researcher Leading the Field in Cancer Immunotherapy by the Medical University of South Carolina.
October 2017
CanCure LLC was selected by NIH NCI small business initiatives to showcase in Life Science Summit in New York in October 31-Nov. 01.
September 2016
CanCure received a STTR Phase I Small Business Award from the NIH/NCI to help advance development of its first-in-class cancer immunotherapeutic antibody, CuraB-10.
July 2016
Dr. Jennifer Wu, CanCure’s Founder and CSO, presented the keynote speech, Beyond Immune Checkpoints: Targeting Soluble NKG2D Ligands for Cancer Immunotherapy at the International Congress of Cancer Immunotherapy Australia.